MK-8189 explained
| Legal Status: | Investigational |
| Cas Number: | 1424371-93-6 |
| Pubchem: | 71271414 |
| Chemspiderid: | 128922007 |
| Stdinchi: | 1S/C19H22N6OS/c1-11-4-5-16(20-8-11)15-6-14(15)10-26-18-7-17(22-12(2)23-18)21-9-19-25-24-13(3)27-19/h4-5,7-8,14-15H,6,9-10H2,1-3H3,(H,21,22,23)/t14-,15+/m1/s1 |
| Stdinchikey: | WQKPZDLZRFTMTI-CABCVRRESA-N |
| Smiles: | CC1=CN=C(C=C1)[C@H]2C[C@@H]2COC3=NC(=NC(=C3)NCC4=NN=C(S4)C)C |
| Iupac Name: | 2-Methyl-6-(1S,2S)-2-(5-methylpyridin-2-yl)cyclopropylmethoxy]-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine |
| C: | 19 |
| H: | 22 |
| N: | 6 |
| O: | 1 |
| S: | 1 |
MK-8189 is a selective phosphodiesterase 10A inhibitor being developed for schizophrenia. It is developed by Merck in collaboration with Royalty Pharma.[1] [2] [3] [4]
Notes and References
- Mukai . Yuki . Lupinacci . Robert . Marder . Stephen . Mackle . Mary . Snow-Adami . Linda . Voss . Tiffini . Smith . Sean . Egan . Michael . P534. Initial Assessment of the Clinical Profile of the PDE10A Inhibitor MK-8189 in Patients With an Acute Episode of Schizophrenia . Biological Psychiatry . May 2022 . 91 . 9 . S305 . 10.1016/j.biopsych.2022.02.771. 248410630 .
- Smith . Sean . Uslaner . Jason . Kandebo . Monika . Hostetler . Eric . Raheem . Izzat . Layton . Mark . Gantert . Liza . Riffel . Kerry . Cox . Christopher . Khalilieh . Sauzanne . De Lepeleire . Inge . Bormans . Guy . Depré . Marleen . de Hoon . Jan . Van Laere . Koen . P546. Preclinical Characterization and Phase 1 Evaluation of the Tolerability, Pharmacokinetics, and Enzyme Occupancy of MK-8189, a Novel PDE10A Inhibitor . Biological Psychiatry . May 2022 . 91 . 9 . S309–S310 . 10.1016/j.biopsych.2022.02.783. 248410556 .
- Layton . Mark E. . Kern . Jeffrey C. . Hartingh . Timothy J. . Shipe . William D. . Raheem . Izzat . Kandebo . Monika . Hayes . Robert P. . Huszar . Sarah . Eddins . Donnie . Ma . Bennett . Fuerst . Joy . Wollenberg . Gordon K. . Li . Jing . Fritzen . Jeff . McGaughey . Georgia B. . Uslaner . Jason M. . Smith . Sean M. . Coleman . Paul J. . Cox . Christopher D. . Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia . Journal of Medicinal Chemistry . 26 January 2023 . 66 . 2 . 1157–1171 . 10.1021/acs.jmedchem.2c01521. 36624931 . 255567942 . free . 9884086 .
- MK-8189: A Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia . Synfacts . April 2023 . 19 . 4 . 0410 . 10.1055/s-0042-1752651. 257614478 .
